Agenus reports impact of key immuno-oncology data presented at leading medical conferences and peer-reviewed publications

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy. agenus is advancing a robust clinical pipeline targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, tumor microenvironment conditioning agents and cell therapies (via mink therapeutics). our most advanced antibody candidates, botensi.
AGEN Ratings Summary
AGEN Quant Ranking